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Treatment decisions in inflammatory bowel diseases are increasingly based on longitudinal
tracking of calprotectin results. Many hospital laboratories measure calprotectin levels in
sent-in stool samples with an enzyme-linked immunosorbent assay (ELISA). Several manu-
facturers introduced a lateral flow–based test with software application that turns a smart-
phone camera into a reader for quantitative measurements. We compared three home tests
(IBDoc, QuantonCal and CalproSmart) and companion ELISA tests (fCAL, IDK-Calprotectin
and Calprotectin-ALP) to see if measurement pairs agreed sufficiently.
Design
A method comparison study was conducted with stool samples from patients with active
or quiescent inflammatory bowel disease. Medical students without any specific laboratory
training carried out the home tests with two iOS (iPhone 6 and 7) and two Android
devices (Samsung Galaxy S6 and Motorola Moto G5 Plus). Two experienced laboratory
technicians measured the calprotectin concentration with the ELISA method. Primary out-
come was test agreement (defined as percentage of paired measurements within prede-
fined limits of difference). Secondary outcome included reading error rate (RER) per
smartphone type.
Results
We performed 1440 smartphone readings and 120 ELISA tests. In the low calprotectin
range (�500 μg/g) IBDoc, QuantOnCal and CalproSmart showed 87%, 82% and 76%
agreement with their companion ELISAs. In the high range (>500 μg/g) the agreement
was 37%, 19% and 37%, respectively. CalproSmart and QuantOnCal had significantly
higher RERs than IBDoc (respectively 5.8% and 4.8%, versus 1.9%). Forty-three percent
of reading errors was on the Motorola device, in particular with the QuantOnCal
application.
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Conclusions
All three calprotectin home tests and companion ELISAs agreed sufficiently when concen-
trations are�500 μg/g. To minimize wrongful interpretation of calprotectin changes over
time it is essential to always use the home test and companion ELISA of one and the same
manufacturer. Manufacturers should explicitly evaluate and report the suitability of com-
monly used smartphones for quantitative calprotectin readings.
Introduction
Treatment decisions in patients with inflammatory bowel disease (IBD) are increasingly based
on longitudinal tracking of stool calprotectin test results. There are indications that calprotec-
tin-guided escalation of therapy results in better short-term clinical and endoscopic outcomes
than symptom-guided decisions alone.[1] Repeated calprotectin concentrations below 250 μg/
g are considered to be a useful treatment target and are synonymous with a low risk for disease
flare.[2]
Many hospital laboratories measure the calprotectin concentration in sent-in stool samples
with an enzyme-linked immunosorbent assay (ELISA). It was generally believed that the pro-
tein was stable in stool samples for up to seven days, [3] but recent experiments have shown
that calprotectin values gradually decline to approximately 65% of baseline levels after 6 days
storage at room temperature.[4, 5] To prevent underestimation of disease activity stool sam-
ples collected at home should be refrigerated until arrival at the hospital laboratory, but this
complicates transport. A more practical solution would be to measure the calprotectin concen-
tration immediately after stool sample collection at home.
A new measurement method has recently been introduced commercially. The method itself
and convenience of use are similar to those of a pregnancy test. By taking a photo of the test
strip with a smartphone, the patient can perform quantitative measurements at home. We
compared three of these home tests (IBDoc, Quanton Cal and CalproSmart) with the ELISA
method of the same manufacturer (fCAL, IDK-Calprotectin and Calprotectin-ALP) to see
which of the pairs has the best agreement. In addition, we evaluated the reading error rate
(RER) per smartphone type.
Methods
Study design and pre-analytical sample handling
This method comparison study was performed at the University Medical Center Groningen
(UMCG, the Netherlands). Between March and May 2018 IBD patients treated at the Depart-
ment of Paediatric Gastroenterology volunteered in donating stool samples for this study.
They defecated onto a stool collection sheet held above the toilet water at home, and trans-
ferred a sample of stool into a classical screw top container with a spatula. They described the
stool consistency by completing the Bristol Stool Form Scale (BSFS), [6] and send both the
screw top container and BSFS in a resealable biomaterial envelope to the Department of Labo-
ratory Medicine. For the purpose of this study the patients themselves were not involved in
the measurement of stool calprotectin. Upon arrival at the laboratory, the stool sample was
homogenized and then aliquoted for analysis with two separate methods. Both aliquots were
stored at -20˚C until analysis.
Calprotectin home tests
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Measurement of stool calprotectin with home test
Three third year medical students without any specific laboratory training carried out the
home tests of three manufacturers (Table 1). Each manufacturer-specific test cassette was read
with four different smartphones which were purchased especially for this project:: two iOS
(iPhone 6 and 7) and 2 Android devices (Samsung Galaxy S6 and Motorola Moto G5 Plus)
(Fig 1). The sequence of use of smartphone type and home test was randomized to prevent
bias. An hour before the testing session the students defrosted one of two aliquots. They all
dipped the assay-specific sampling pin in the sample and transferred the fecal material into the
assay-specific tube with extraction buffer. After observing the advised extract processing time,
they then applied a drop of extraction fluid in the measurement window of the test cassette as
per manufacturer’s instructions. After the appropriate incubation time the cassette was read
with the smartphone by placing the camera above the cassette. The image was automatically
analyzed by the smartphone application and the quantitative calprotectin result was directly
shown on the smartphone screen.
Measurement of stool calprotectin with ELISA
Experienced laboratory technicians, who were blinded for the smartphone readings, thawed
the second aliquot and carried out batch ELISA testing with three assays that corresponded
with the home tests (see Table 1). The samples were manually weighted and the measurements
were done on a Dynex DS2 automated ELISA system (Alpha Labs, Easleigh, UK).
Outcome measures
The agreement between the home test and the companion ELISA measurement was consid-
ered as the primary outcome measurement, and was analyzed with a Bland-Altman plot. As
described previously [7], we reasoned that disagreement in the lower range of the tests (i.e.,
below 500 μg/g) could lead more easily to misclassification of disease activity than disagree-
ment in the higher range (>500 μg/g). We therefore used predefined acceptable limits of






App name IBDoc QuantOn Cal CalproSmart
Extract processing time 2–24 hours Not specified Not specified
Incubation time test cassette 12 minutes 15 minutes 15 minutes
Test analysis time 2 minutes 2 minutes 2 minutes
Measuring range (μg/g) 30–1000 μg/g 25–2000 μg/g 70–1500 μg/g
Suitability of smartphone for single-snapshot reading of cassette
iPhone 6 yes yes yes
iPhone 7 yes yes yes
Motorola Moto G5 plus no yes yes
Samsung Galaxy S6 yes yes yes
ELISA
Name BU¨HLMANN fCAL IDK Calprotectin Calprotectin (ALP)
Measuring range (μg/g) 30–1800 μg/g 25,5–2100 μg/g 25–2500 μg/g
Interassay coefficients of variation 7.8–12.8% 9.1–11.6% 4.8–13%
(derived from the manufacturer’s statements in the instruction for use).
https://doi.org/10.1371/journal.pone.0214751.t001
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difference, which were arbitrary set at ±100 ug/g for the lower range, and ±200 μg/g for the
higher range. Secondly, concordance of home test and companion ELISA test were determined
in each of 3 calprotectin ranges commonly used in our clinical practice (i.e.,<250 μg/g for tar-
get range, 250–500 μg/g for undecisive range, and>500 μg/g for active disease).[7] Other out-
come measures included the reading error rate (RER) per smartphone type, with reading error
defined as an image of the test cassette not leading to quantitative result, and evaluation of the
usability of the home test and the smartphone application on the first, seventh and last day of
the home test experiments. For that purpose, the students completed the system usability scale
Fig 1. Study flow. We used 40 stool samples that covered the whole range of potential calprotectin values and
performed 1440 smartphone readings and 120 ELISA measurements.
https://doi.org/10.1371/journal.pone.0214751.g001
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(SUS).[8] The SUS is a simple, ten item scale giving a global view of subjective assessments of
usability and learnability of a system. Scores have a range of 0 to 100, and should be considered
as grade scales rather than percentages.
Sample size calculation
The primary outcome was taken as the overall percentage of agreement between the calprotectin
home test and the corresponding ELISA test per manufacturer. We wished to detect a difference
in agreement of at least 15% by a two-sided test. With the level of significance set at 5% and a
study power of 80%, we aimed to include at least 110 paired measurements per manufacturer.
Statistical analysis
In Bland-Altman analysis, a scatter plot is constructed in which the difference between the
paired measurements is plotted on the vertical axis and the average of the measures of two
methods on the horizontal axis. The mean difference in values obtained with the two methods
is called the bias and is represented by a central horizontal line on the plot. The standard devia-
tion (SD) of differences between paired measurements is used to construct horizontal lines
above and below the line to represent 95% limits of agreement (LOA). The plot enables the
reader to visually assess the bias, data scatter and the relationship between magnitude of differ-
ence and size of measurement. ELISA measurements out of the measurable range of the home
test were rounded to the upper limit of the home test range. In addition, we provide a distribu-
tion histogram of the differences between the paired measurements in the low range calprotec-
tin concentrations. Concordance of home test and companion ELISA readings in each of the
three calprotectin ranges are presented in a scatterplot. RERs per home test and smartphone
type are reported as percentages with confidence intervals. Data were recorded electronically
by using SPSS version 23.0 for Apple Mac (IBM Corporation, Armonk, NY). Graphs were con-
structed with GraphPad Prism version 7 for MacBook (GraphPad Software, San Diego, Cali-
fornia USA). P-values <0.05 were considered statistically significant.
Ethical consideration
The Medical Ethics Review Committee of the University Medical Center Groningen waived
consent requirement for this specific study, as no human subjects as meant in the Dutch Medi-
cal Research Involving Human Subjects Act (WMO) were involved. Nonetheless legal guard-
ians from all participants, as well as the children aged 12 and above, gave informed consent to
use their voluntary stool samples for research. This study was conducted in compliance with
the Clinical Trial Agreement, the study protocol, designated Standard Operating Procedures
and the international standard for studies for In Vitro Diagnostic Medical Devices. (ISO
22870: 2016 Point-of-care testing (POCT)–Requirements for quality and competence). All
authors had access to the study data and reviewed and approved the final manuscript.
Results
Between March and May 2018, we selected 40 stool samples, of which 23 (58%) were in the
low calprotectin range (<500 μg/g) and 17 (42%) in the high range (�500 μg/g). Per homoge-
nized stool sample 36 smartphone readings and 3 ELISA measurements were done.
Bland-Altman analysis
In Table 2 we show the agreement between home test and corresponding ELISA per manufac-
turer using the Bland-Altman plot analysis. IBDoc underestimated the fCAL ELISA results
Calprotectin home tests
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over the whole range of potential calprotectin values with a mean bias of 105 μg/g (agreement
interval 942 μg/g). QuantOn Cal overestimated IDK-Calprotectin ELISA results with a mean
bias of 137 μg/g (agreement interval 1574 μg/g). CalproSmart overestimated Calprotectin-ALP
ELISA results with a mean bias of 141 μg/g (agreement interval 914 μg/g). Fig 2 shows that in
all comparisons the paired measurements were more clustered and closer to the zero-differ-
ence line in the low calprotectin range and more scattered in the high range.
Low calprotectin range (� 500 μg/g). In the low calprotectin range the percentage of
paired measurements within acceptable limits of difference for IBDoc, QuantOn Cal and Cal-
proSmart were 87% (263/304), 82% (285/349) and 76% (235/310), respectively. Fig 3 shows
that the difference scores for IBDoc, QuantOn Cal and CalproSmart were distributed in an
approximately normal pattern around the bias of -19 μg/g (agreement interval 560 μg/g),
-4 μg/g (agreement interval 455 μg/g) and 72 μg/g (agreement interval 458 μg/g), respectively.
The agreement interval of all three comparisons exceeded the acceptable limits of difference in
the low range (i.e. 200 μg/g).
High calprotectin range (>500 μg/g). In the high calprotectin range the percentage of
paired measurements within acceptable limits of difference for IBDoc, QuantOn Cal and Cal-
proSmart were 37% (61/167), 19% (20/108) and 37% (52/142), respectively. The difference
scores were not normally distributed around the bias (data not shown). The bias for IBDoc,
QuantOn Cal and CalproSmart was -262 μg/g (agreement interval 1160 μg/g), 591 μg/g (agree-
ment interval 2392 μg/g) and 293 μg/g (agreement interval 1310 μg/g), respectively. The agree-
ment interval of all three comparisons exceeded the acceptable limits of difference in the high
range (i.e. 400 μg/g).
Table 2. Agreement of results between three different home test and corresponding ELISA using Bland-Altman plot analysis.



















IBDoc vs BU¨HLMANN fCAL
iPhone 7 -129 -595–337 932 -22 -295–252 548 -332 -827–164 991
iPhone 6 -87 -541–367 908 -1 -291–290 581 -246 -780–288 1067
Motorola Moto
G5 Plus
-111 -617–395 1012 -41 -342–261 603 -240 -921–442 1363
Samsung Galaxy -93 -589–363 952 -13 -270–243 513 -232 -819–356 1175
Overall -105 -576–366 942 -19 -299–261 560 -262 -842–318 1160
QuantOn Cal vs IDK Calprotectin
iPhone 7 115 -608–838 1446 -6 -255–243 498 514 -613–1640 2253
iPhone 6 169 -691–1029 1720 -12 -150–127 277 689 -509–1887 2396
Motorola Moto
G5 Plus
97 -678–872 1550 -7 -257–242 499 495 -902–1893 2795
Samsung Galaxy 160 -627–947 1574 9 -247–265 512 633 -486–1752 2239
Overall 137 -650–924 1574 -4 -232–223 455 591 -605–1787 2392
CalproSmart vs Calprotectin (ALP)
iPhone 7 159 -306–624 930 82 -170–333 503 322 -308–952 1259
iPhone 6 170 -294–661 955 88 -158–334 491.6 342 -337–1022 1359
Motorola Moto
G5 Plus
139 -321–599 920 71 -156–298 454.4 300 -379–978 1357
Samsung Galaxy 99 -307–506 813 48 -136–232 367 212 -418–843 1260
Overall 141 -316–598 914 72 -157–301 458 293 -362–948 1310
A negative number in the “bias” column indicates that use of the home test underestimates the calprotectin concentration as compared to the ELISA method.
https://doi.org/10.1371/journal.pone.0214751.t002
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Fig 2. Bland-Altman plots showing difference against mean for (A) IBDoc vs. fCAL; (B) QuantOn Cal vs. IDK
Calprotectin; and (C) CalproSmart vs. Calprotectin (ALP). The grey zone corresponds with the predefined
acceptable limits of difference, which were arbitrary set at ±100 μg/g for the lower range and at ±200 μg/g for the
higher range.[7] The dotted line is the bias (mean of the differences), the dashed lines are the upper and lower 95%
limits of agreement (LOA).
https://doi.org/10.1371/journal.pone.0214751.g002
Calprotectin home tests
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Concordance
Fig 4 shows the concordance between home tests and corresponding ELISA tests in each of
three ranges (i.e., <250, 250–500 and>500 μg/g) that we use in our clinical practice. Of the
Fig 3. Histogram of differences in calprotectin concentrations (μg/g) for (A) IBDoc minus fCAL; (B) QuantOn
Cal minus IDK Calprotectin; and (C) CalproSmart minus Calprotectin (ALP).
https://doi.org/10.1371/journal.pone.0214751.g003
Calprotectin home tests
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Fig 4. Simplified concordance matrices showing calprotectin readings with (A) IBDoc against fCAL; (B)
QuantOn Cal against IDK Calprotectin; and (C) CalproSmart against Calprotectin (ALP).
https://doi.org/10.1371/journal.pone.0214751.g004
Calprotectin home tests
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IBDoc-fCAL pairs 358 of 471 (82%) were concordant. Discordance between the IBDoc-fCAL
pairs leading to serious misclassification of disease activity (i.e., calprotectin >500 μg/g with
one method and<250 μg/g with the other) were observed in 24 of 471 stool samples (5%).
QuantOn Cal and IDK-Calprotectin had 361 of 457 (79%) concordant test pairs, and 35 of 457
(8%) discordant test pairs leading to serious misclassification of disease activity. CalproSmart
and Calprotectin-ALP had 330 of 452 (73%) concordant test pairs, and 11 of 452 (2%) seriously
discordant test pairs.
Reading error rate
The CalproSmart and QuantOn Cal smartphone applications had significantly more reading
errors than the IBDoc application, with rates of respectively 5.8% and 4.8% versus 1.9%
(P = 0.002 and P = 0.012). Forty-three percent of the total amount of reading errors was with
the Motorola device, in particular in combination with the QuantOn Cal application (Fig 5).
Common reason for reading errors was an out of focus image.
System usability scale
Fig 6 shows that mean SUS scores per home test were lowest on the first day of testing. On the
last day of testing IBDoc was awarded the highest grade (B) of all home tests, mainly because
the smartphone application was error-friendly and therefore less cumbersome to use.
Discussion
This is the first head-to-head method comparison study investigating three calprotectin home
tests and their companion ELISA tests. We have shown that the majority of measurements per-
formed with a lateral flow immunoassay and smartphone reader agreed sufficiently with the
ELISA-based quantification of the same manufacturer, provided that calprotectin levels are
Fig 5. Reading error rate per home test for different smartphone types.
https://doi.org/10.1371/journal.pone.0214751.g005
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below 500 μg/g. In the high calprotectin range a substantial proportion of measurement pairs
exceeded the predefined limits of difference (±200 μg/g). QuantOn Cal performed significantly
poorer in the high range than IBDoc and CalproSmart. IBDoc had significantly fewer reading
errors than the other two applications. The Motorola device turned out to be less suitable for
calprotectin readings than the other smartphone types. A complete summary of the test perfor-
mance per manufacturer is shown in S1 Table.
The possibility to measure calprotectin with a smartphone at home is a novelty in IBD-care.
We identified three recently published studies on the IBDoc home test, [7, 9, 10] and one on
the CalproSmart home test.[11] All studies showed acceptable agreement between home test
and companion ELISA in the low range and lack of agreement in the high range. These studies
differ from ours in several important ways. First, in three of the aforementioned studies, home
tests were performed before shipping the unrefrigerated stool samples to the laboratory.[7, 10,
11] The possible decline in calprotectin during transport may have affected the agreement
with the ELISA results, while in our experiment the transport of stool samples was taken out of
the equation. Second, none of the studies performed a subgroup analysis per smartphone type,
while we compared several iOS and Android devices. By doing so, we were able to show that
not all smartphone cameras were suitable for calprotectin readings. Third, in this study we
report an a priori decision of acceptable limits of difference for adequate interpretation of the
Bland-Altman plot, a feature that was absent in three of the aforementioned studies.[9–11]
Precision is of utmost importance in the low ranges of calprotectin values, where small devia-
tions can lead to misclassification of disease activity and wrong treatment decisions. In our
practice, however, imprecision in the high range is less of an issue, since we consider each cal-
protectin result >500 μg/g to reflect active disease, irrespective of the absolute concentration.
A twofold increase in calprotectin, e.g. from 1000 to 2000 μg/g, does not necessarily mean that
the inflamed surface area of the gastrointestinal tract doubled, neither that the intensity of the
inflammation increased. Any shift of calprotectin values out of the target range, and into the
action range (� 500 μg/g) is a trigger for us to change the treatment plan. In order to
Fig 6. Student’s mean system usability scale (SUS) scores on day 1, 7 and day 10 of testing. SUS scores above 90 should be converted to “A”; 80–90
to “B”; 70–80 to “C”; 60–70 to “D”; and below 60 to “F”.
https://doi.org/10.1371/journal.pone.0214751.g006
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appreciate the true value of the home tests in the high range, we also evaluated the concor-
dance with companion ELISAs. We observed that 119 of 125 IBDoc readings� 500 μg/g were
concordant with fCAL results (95%), compared to 35% and 49% for the QuantOnCal—IDK-
Calprotectin and CalproSmart—Calprotectin-ALP pairs.
There are some limitations in our study that need to be addressed. First, the home tests
were not performed by real IBD patients. Instead, we had three 3rd year medical students (AG,
SA, JAAB) without any specific laboratory training to fill the lateral flow cassettes and execute
the smartphone readings. They only had access to the instructions for use and video tutorials
on the internet. We acknowledge that their level of education is higher than the “average IBD
patient”. Second, although we aimed to collect stool samples that covered the whole range of
potential consistencies, we missed the liquid samples. For that reason we were unable to evalu-
ate the effect of stool consistency on the precision of the lateral flow-based method.
The evidence base for calprotectin-guided treatment escalation and de-escalation is accu-
mulating.[1, 2, 12] Simultaneously, the number of telemonitoring initiatives for IBD care is ris-
ing.[13–16] Telemonitoring with calprotectin home testing can make the service to IBD
patients more efficient, as the technology allows to select and target patients that benefit from
a face-to-face encounter with their IBD-team at short notice.
We evaluated by how much the home tests differed from the trusted ELISA method, and
found that in the lower ranges the difference was small enough not to cause problems in inter-
pretation. We conclude that the flow-based home-test and the companion ELISA method can
be used interchangeably. To minimize wrongful interpretation of calprotectin changes over
time it is essential to always use the home test and companion ELISA of one and the same
manufacturer. This advice was already in force for the use of ELISA tests.[17–20] Ultimately,
patients and health care providers would both benefit from better co-calibration of stool cal-
protectin assays.
Supporting information
S1 Table. Summary of performance of calprotectin home tests.
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